busulfan has been researched along with Anaplastic Ependymoma in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 9.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 5.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gururangan, S | 1 |
| Petros, WP | 1 |
| Poussaint, TY | 1 |
| Hancock, ML | 1 |
| Phillips, PC | 1 |
| Friedman, HS | 3 |
| Bomgaars, L | 1 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Grill, J | 2 |
| Kalifa, C | 2 |
| Doz, F | 1 |
| Schoepfer, C | 1 |
| Sainte-Rose, C | 1 |
| Couanet, D | 1 |
| Terrier-Lacombe, MJ | 1 |
| Valteau-Couanet, D | 1 |
| Hartmann, O | 1 |
| Graham, ML | 1 |
| Herndon, JE | 1 |
| Casey, JR | 1 |
| Chaffee, S | 1 |
| Ciocci, GH | 1 |
| Krischer, JP | 1 |
| Kurtzberg, J | 1 |
| Laughlin, MJ | 1 |
| Longee, DC | 1 |
| Olson, JF | 1 |
| Paleologus, N | 1 |
| Pennington, CN | 1 |
| Coggins, CA | 1 |
| Elion, GB | 1 |
| Houghton, PJ | 1 |
| Hare, CB | 1 |
| Keir, S | 1 |
| Colvin, OM | 1 |
| Bigner, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis[NCT00006246] | Phase 1 | 28 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors[NCT02684071] | Phase 2 | 3 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Lack of additional funding; patients (3) no longer receiving intervention.) | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for busulfan and Anaplastic Ependymoma
| Article | Year |
|---|---|
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neopl | 1996 |
3 other studies available for busulfan and Anaplastic Ependymoma
| Article | Year |
|---|---|
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1997 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
High dose chemotherapy for childhood ependymona.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1998 |